Skip to Content
Merck

Key Documents

View All Documentation

Skip To

O-024

Olanzapine solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C17H20N4S
CAS Number:
132539-06-1
Molecular Weight:
312.43
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-835-2
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChI key

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813), DRD3(1814), DRD4(1815), HTR2A(3356), HTR2C(3358)

General description

An analytical reference standard for use in LC/MS or GC/MS applications including clinical toxicology analysis or therapeutic drug monitoring. Marketed under the trade name Zyprexa®, olanzapine is an atypical antipsychotic drug used in the treatment of schizophrenia and bipolar disorder.

Legal Information

Zyprexa is a registered trademark of Eli Lilly and Co.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
Y00013701478301BP1060
Olanzapine solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

O-024

Olanzapine solution

Olanzapine European Pharmacopoeia (EP) Reference Standard

Y0001370

Olanzapine

Olanzapine United States Pharmacopeia (USP) Reference Standard

USP

1478301

Olanzapine

Olanzapine British Pharmacopoeia (BP) Reference Standard

BP1060

Olanzapine

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

-

technique(s)

-

technique(s)

-

format

single component solution

format

neat

format

neat

format

neat

form

liquid

form

-

form

-

form

solid

Quality Level

300

Quality Level

-

Quality Level

-

Quality Level

-

grade

certified reference material

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

pictograms

FlameExclamation mark
GHS02,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Heating under high-frequency inductive conditions: application to the continuous synthesis of the neurolepticum olanzapine (Zyprexa).
Jan Hartwig et al.
Angewandte Chemie (International ed. in English), 52(37), 9813-9817 (2013-07-31)
Joseph P McEvoy et al.
The Journal of clinical psychiatry, 74(2), 170-179 (2013-03-12)
To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2
Jean A Milstein et al.
PloS one, 8(2), e57308-e57308 (2013-02-26)
Antipsychotic drugs are increasingly used in children and adolescents to treat a variety of psychiatric disorders. However, little is known about the long-term effects of early life antipsychotic drug treatment. Most antipsychotic drugs are potent antagonists or partial agonists of
View All Related Papers

Global Trade Item Number

SKUGTIN
O-024-1ML04061834211808

Questions

Reviews

No rating value

Active Filters